Ingolf Griebsch (PharmD, MPH, MSc, PhD) is an outcome researcher and health economist who leads the global market access team in the therapeutic area oncology at the headquarters of Boehringer Ingelheim in Germany. Ingolf co-leads Work Package 1. He has 18+ years’ experience in designing and conducting cost-effectiveness analyses using trial based and decision-analytical modelling approaches, patient-reported outcome studies and analyses and various other outcome research projects to describe the burden of disease and real world effectiveness. He currently supervises and manages a team of five health economists and market access managers, responsible for devising outcome and market access strategies for the marketed and pipeline Oncology portfolio of BI. He has over 30 peer-reviewed publications covering applied studies in health economics and patient-reported outcomes as well as methodological aspects of health technology assessment approaches. Ingolf was the co-initiator and founding member of the “Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints Data” (SISAQOL) Consortium, which involves an international, multi-stakeholder group of experts whose goal is to develop recommendations for the analysis of PRO and QOL data in cancer clinical trials.